Targeting SPHK1/S1P to modify the therapeutic strategy of tumor patients is a promising approach to enhance the response to immune checkpoint inhibitors in mouse melanoma, breast, and colon cancer models [42]. Here, MBTPS1 is linked to malignant colon neoplasm.